Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding

• Published in: Antimicrobial agents and chemotherapy Vol. 61; no. 2
• Main Authors: Foissac, Frantz, Blume, Jörn, Tréluyer, Jean-Marc, Tylleskär, Thorkild, Kankasa, Chipepo, Meda, Nicolas, Tumwine, James K, Singata-Madliki, Mandisa, Harper, Kim, Illamola, Silvia M, Bouazza, Naïm, Nagot, Nicolas, Van de Perre, Philippe, Blanche, Stéphane, Hirt, Déborah
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.02.2017
• Subjects: Anti-HIV Agents; Anti-HIV Agents - therapeutic use; Bayes Theorem; Breast Feeding; Breast Feeding - adverse effects; HIV Infections; HIV Infections - prevention & control; Humans; Infant; Infectious Disease Transmission, Vertical; Infectious Disease Transmission, Vertical - prevention & control; Lamivudine; Lamivudine - therapeutic use; Life Sciences; Lopinavir; Lopinavir - therapeutic use; Microbiology and Parasitology; Mothers; Pharmaceutical sciences; Pharmacology; Ritonavir; Ritonavir - therapeutic use; preexposure prophylaxis; pharmacokinetics; breastfeeding
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.01869-16

The ANRS 12174 trial assessed the efficacy and tolerance of lopinavir (LPV)-ritonavir (LPV/r) prophylaxis versus those of lamivudine (3TC) prophylaxis administered to breastfed infants whose HIV-infected mothers were not on antiretroviral therapy. In this substudy, we assessed LPV/r and 3TC pharmacokinetics to evaluate the percentage of infants with therapeutic plasma concentrations and to discuss these data in the context of a prophylactic treatment. Infants from the South African trial site underwent blood sampling for pharmacokinetic study at weeks 6, 26, and 38 of life. We applied a Bayesian approach to derive the 3TC and LPV pharmacokinetic parameters on the basis of previously published pharmacokinetic models for HIV-infected children. We analyzed 114 LPV and 180 3TC plasma concentrations from 69 infants and 92 infants, respectively. A total of 30 LPV and 20 3TC observations were considered missing doses and discarded from the Bayesian analysis. The overall population analysis showed that 30 to 40% of the infants did not reach therapeutic targets, regardless of treatment group. The median LPV trough concentrations at weeks 6, 26, and 38 were 2.8 mg/liter (interquartile range [IQR], 1.7 to 4.4 mg/liter), 5.6 mg/liter (IQR, 3.2 to 7.7 mg/liter), and 3.4 mg/liter (IQR, 2.3 to 7.3 mg/liter), respectively. The median 3TC area under the curve from 0 to 12 h after the last drug intake were 5.6 mg · h/liter (IQR, 4.1 to 7.8 mg · h/liter), 5.9 mg · h/liter (IQR, 5.1 to 7.5 mg · h/liter), and 7.3 mg · h/liter (IQR, 4.9 to 8.5 mg · h/liter) at weeks 6, 26, and 38, respectively. Use of the therapeutic doses recommended by the WHO would have resulted in a higher proportion of infants achieving the targets. However, no HIV-1 infection was reported among these infants. These results suggest that the prophylactic targets for both 3TC and LPV may be lower than the therapeutic ones. For treatment, the WHO dosing guidelines should be suitable to maintain values above the therapeutic pharmacokinetic targets in most infants. (This study has been registered at ClinicalTrials.gov under identifier NCT00640263.).